DK2882496T3 - Behandling og diagnosticering af melanom - Google Patents

Behandling og diagnosticering af melanom Download PDF

Info

Publication number
DK2882496T3
DK2882496T3 DK13829165T DK13829165T DK2882496T3 DK 2882496 T3 DK2882496 T3 DK 2882496T3 DK 13829165 T DK13829165 T DK 13829165T DK 13829165 T DK13829165 T DK 13829165T DK 2882496 T3 DK2882496 T3 DK 2882496T3
Authority
DK
Denmark
Prior art keywords
diagnostication
melanoma
treatment
Prior art date
Application number
DK13829165T
Other languages
English (en)
Inventor
Sohail Tavazoie
Nora G Pencheva
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of DK2882496T3 publication Critical patent/DK2882496T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
DK13829165T 2012-08-13 2013-08-13 Behandling og diagnosticering af melanom DK2882496T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682339P 2012-08-13 2012-08-13
US201361784057P 2013-03-14 2013-03-14
PCT/US2013/054690 WO2014028461A2 (en) 2012-08-13 2013-08-13 Treatment and diagnosis of melanoma

Publications (1)

Publication Number Publication Date
DK2882496T3 true DK2882496T3 (da) 2019-11-11

Family

ID=50101591

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13829165T DK2882496T3 (da) 2012-08-13 2013-08-13 Behandling og diagnosticering af melanom

Country Status (10)

Country Link
US (8) US9399028B2 (da)
EP (3) EP3626309B1 (da)
JP (6) JP6320382B2 (da)
CN (3) CN104780976B (da)
AU (4) AU2013302861A1 (da)
CA (2) CA3211094A1 (da)
DK (1) DK2882496T3 (da)
ES (2) ES2765573T3 (da)
HU (1) HUE046292T2 (da)
WO (1) WO2014028461A2 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0913578A2 (pt) 2008-05-14 2017-06-06 Dermtech Int diagnose de melanoma e lentigo solar por análise de ácido nucléico
EP3441390A1 (en) 2012-03-02 2019-02-13 Ralexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
ES2765573T3 (es) * 2012-08-13 2020-06-09 Univ Rockefeller Tratamiento y diagnóstico de melanoma
SG11201601644RA (en) 2013-09-04 2016-04-28 Alexar Therapeutics Inc Liver x receptor (lxr) modulators
AU2014315280B2 (en) 2013-09-04 2019-01-24 Ellora Therapeutics, Inc. Liver X receptor (LXR) modulators
EP3091970B1 (en) * 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
US20190125745A1 (en) * 2014-12-17 2019-05-02 Rgenix, Inc. Treatment and diagnosis of cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10709428B2 (en) 2015-05-01 2020-07-14 Dermtech, Inc. Non-invasive skin collection system
US11795496B2 (en) * 2015-06-24 2023-10-24 Oxford BioDynamics PLC Epigenetic chromosome interactions
US20200046671A1 (en) * 2015-06-29 2020-02-13 Regents Of The University Of Minnesota Apobec3b mutagenesis and immunotherapy
JP2018527895A (ja) 2015-06-29 2018-09-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法
US11648220B2 (en) 2016-01-11 2023-05-16 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
US11208468B2 (en) 2016-02-18 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI786044B (zh) * 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
EP3481400A4 (en) * 2016-07-11 2020-04-01 Dana-Farber Cancer Institute, Inc. METHODS OF TREATING PTEN-DEFICIENT EPITHELIAL CANCERS USING A COMBINATION OF ANTI-PI3KBETA AND ANTI-CONTROL POINT AGENTS
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
CN110494415A (zh) * 2017-03-03 2019-11-22 睿治尼斯公司 具有改善的稳定性的制剂
CN106890315B (zh) * 2017-03-16 2019-09-06 北京热休生物技术有限公司 Apo-e蛋白及其多肽在治疗与预防癌症中的应用
JP7405408B2 (ja) * 2017-05-16 2023-12-26 バイオメッド バレー ディスカバリーズ，インコーポレイティド 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
BR112021010234A2 (pt) * 2018-11-28 2021-08-24 Prevail Therapeutics, Inc. Terapias de gene para doença neurodegenerativa
US20220127680A1 (en) * 2019-02-28 2022-04-28 The Rockefeller Universtiy Apoe genotyping in cancer prognostics and treatment
AU2020247911A1 (en) 2019-03-26 2021-11-11 Dermtech, Llc Novel gene classifiers and uses thereof in skin cancers
EP3752524A4 (en) * 2019-04-27 2021-11-24 Ocugen, Inc. ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASE
CN110218235B (zh) * 2019-05-09 2020-09-25 中山大学 一种化合物及其制备方法和作为荧光偏振探针在LXRβ配体筛选中的应用
EP4027989A4 (en) * 2019-09-11 2023-09-06 Inspirna, Inc. METHOD FOR TREATING CANCER
AU2020355125A1 (en) 2019-09-27 2022-04-14 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
RU2716811C1 (ru) * 2019-11-14 2020-03-16 федеральное государственное бюджетное образовательное учреждение высшего образования "Новгородский государственный университет имени Ярослава Мудрого" Способ ранней диагностики поверхностно распространяющихся меланом
EP4073025B1 (en) 2019-12-13 2024-03-27 Inspirna, Inc. Metal salts and uses thereof
EP4081302A4 (en) * 2019-12-23 2025-01-29 University Of Massachusetts OLIGONUCLEOTIDES FOR TISSUE-SPECIFIC GENE EXPRESSION MODULATION
CA3189491A1 (en) * 2020-08-21 2022-02-24 Csl Behring Ag Cd91 polypeptide for use in detecting hemopexin:heme complex
US20250075217A1 (en) * 2021-07-30 2025-03-06 Alnylam Pharmaceuticals, Inc. Peptide ligands for cns and ocular delivery of rnai compounds
CN114276999A (zh) * 2022-03-03 2022-04-05 中日友好医院(中日友好临床医学研究所) 黑素瘤细胞株及其制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5676978A (en) 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US5324731A (en) 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5215882A (en) 1989-11-30 1993-06-01 Ortho Diagnostic Systems, Inc. Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
DE69621507T2 (de) 1995-03-28 2003-01-09 Japan Science And Technology Corp., Kawaguchi Verfahren zur molekularen Indexierung von Genen unter Verwendung von Restriktionsenzymen
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US5958342A (en) 1996-05-17 1999-09-28 Incyte Pharmaceuticals, Inc. Jet droplet device
US6060240A (en) 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
ES2276481T3 (es) 1997-12-12 2007-06-16 The University Of Western Ontario Peptido apoep1.b novedoso, composiciones y sus usos.
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6048695A (en) 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
US6087112A (en) 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US8257750B2 (en) 1999-04-30 2012-09-04 Kibow Biotech, Inc. Calcium carbonate compositions for preventing or treating hyperphosphatemia
AU2001280576A1 (en) 2000-07-18 2002-01-30 Uab Research Foundation Tissue-specific self-inactivating gene therapy vector
US20030027335A1 (en) 2000-09-07 2003-02-06 Ruley H. Earl Genome engineering by cell-permeable DNA site-specific recombinases
US20040072868A1 (en) 2000-09-18 2004-04-15 Collins Jon Loren Substitued aminopropoxyaryl derivatives useful as agonists for lxr
AU2002219718A1 (en) 2000-12-13 2002-06-24 Sca Hygiene Products Zeist B.V. Process for oxidising primary alcohols
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
WO2003082802A1 (en) * 2002-03-27 2003-10-09 Smithkline Beecham Corporation Acid and ester compounds and methods of using the same
WO2003082205A2 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
AU2003220558A1 (en) 2002-03-27 2004-06-03 Smithkline Beecham Corporation Amide compounds and methods of using the same
WO2004009765A2 (en) 2002-07-19 2004-01-29 Althea Technologies, Inc. Strategies for gene expression analysis
US20040216178A1 (en) 2003-03-03 2004-10-28 Jones Stephen N Regulation of mdm2 function
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005007877A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Regulatable promoters for synthesis of small hairpin rna
ES2342397T3 (es) 2003-10-20 2010-07-06 Nsgene A/S Vector virico para su uso en terapia genica in vivo de la enfermedad de parkinson.
PE20050676A1 (es) 2003-12-12 2005-11-02 Wyeth Corp Quinolinas referidas a enfermedades cardiovasculares
FR2865736B1 (fr) 2004-02-02 2006-07-14 Synt Em Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
WO2005112620A2 (en) 2004-05-18 2005-12-01 Massachusetts Institute Of Technology A cre-lox based method for conditional rna interference
TW200606157A (en) * 2004-07-02 2006-02-16 Sankyo Co Suppressant of production of tissue factor
JP2008505905A (ja) 2004-07-07 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
ES2315912T3 (es) 2004-10-01 2009-04-01 F. Hoffmann-La Roche Ag Derivados de eter sustituido por hexafluorisopropanol.
CN101087754B (zh) 2004-12-22 2012-01-18 霍夫曼-拉罗奇有限公司 环己烷衍生物
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500056D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
KR20070094963A (ko) 2005-01-10 2007-09-27 아스트라제네카 아베 간 ｘ 수용체 조절제로서 이소티아졸-3(2ｈ)-온1,1-디옥사이드 유도체
WO2006073364A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators
SE0500058D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
KR20070116060A (ko) 2005-03-01 2007-12-06 와이어쓰 신놀린 화합물 및 간 ｘ 수용체 조절제로서의 이의 용도
CN101146762A (zh) 2005-03-21 2008-03-19 默克公司 取代的芳基和杂芳基衍生物
WO2007002563A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
WO2007092065A2 (en) 2005-11-14 2007-08-16 Irm Llc Compounds and compositions as lxr modulators
WO2007081335A1 (en) 2006-01-12 2007-07-19 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
US20100279918A1 (en) 2006-03-20 2010-11-04 Burnham Institute For Medical Research Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents
WO2008011071A2 (en) * 2006-07-19 2008-01-24 The Regents Of The University Of California Interactions of hedgehog and liver x receptor signaling pathways
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
EP2098515B1 (en) 2006-11-30 2012-02-08 Kowa Company, Ltd. Substituted carbinol compound
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
JP2008179562A (ja) 2007-01-24 2008-08-07 Kowa Co Ｌｘｒアゴニスト
US8993628B2 (en) 2007-02-23 2015-03-31 City Of Hope Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
MX2009012474A (es) 2007-05-18 2009-12-18 Wyeth Corp Compuestos de quinazolina.
WO2009005793A2 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
CN103772299A (zh) 2007-08-13 2014-05-07 霍夫曼-拉罗奇有限公司 新型哌嗪酰胺衍生物
TW200922582A (en) 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
US8039493B2 (en) 2007-09-27 2011-10-18 Hoffmann-La Roche Inc. Biaryl sulfonamide derivatives
ES2463665T3 (es) * 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
WO2009075836A2 (en) * 2007-12-10 2009-06-18 The Brigham And Women's Hospital, Inc. Rap variants for drug delivery
BRPI0821315A2 (pt) 2007-12-21 2019-09-24 Wyeth Llc compostos benzimidazol
WO2009086130A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
CN101952293A (zh) 2007-12-21 2011-01-19 惠氏有限责任公司 吡唑并[1,5-a]嘧啶化合物
BRPI0822237A2 (pt) 2007-12-21 2015-06-30 Wyeth Llc Compostos de imidazo [1,2-a] piridina
EP2248811B1 (en) 2008-02-29 2012-11-14 Kowa Company, Ltd. 2-oxochromene derivative
WO2009148915A2 (en) * 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
WO2010002982A1 (en) * 2008-07-01 2010-01-07 Cognosci, Inc. Methods of treating cancer with apoe peptides
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
WO2010101888A2 (en) * 2009-03-02 2010-09-10 Biocure Pharma, Llc Methods and compositions for treatment of tumor metastasis
HRP20170194T1 (hr) 2009-05-28 2017-05-19 Exelixis Patent Company Llc Lxr modulatori
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2011130426A2 (en) * 2010-04-13 2011-10-20 New York University Compositions and methods for treatment of melanoma
US20130090258A1 (en) 2010-06-16 2013-04-11 National University Corporation Hamamatsu University School Of Medicines Method for detecting colorectal tumor
EP2474617A1 (en) * 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
US20130071403A1 (en) * 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
ES2765573T3 (es) * 2012-08-13 2020-06-09 Univ Rockefeller Tratamiento y diagnóstico de melanoma

Also Published As

Publication number Publication date
JP2026062949A (ja) 2026-04-10
EP2882496B1 (en) 2019-10-09
ES2765573T3 (es) 2020-06-09
US20240252458A1 (en) 2024-08-01
AU2013302861A1 (en) 2015-03-05
EP4218935A1 (en) 2023-08-02
US20170319525A1 (en) 2017-11-09
US20150023955A1 (en) 2015-01-22
US9707195B2 (en) 2017-07-18
US11865094B2 (en) 2024-01-09
US12502368B2 (en) 2025-12-23
EP3626309B1 (en) 2023-03-08
US9526710B2 (en) 2016-12-27
US20160331726A1 (en) 2016-11-17
WO2014028461A2 (en) 2014-02-20
CA2882292C (en) 2023-10-17
ES2941477T3 (es) 2023-05-23
CA2882292A1 (en) 2014-02-20
CN110037999A (zh) 2019-07-23
AU2018226488B2 (en) 2020-01-23
JP6320382B2 (ja) 2018-05-09
US9962348B2 (en) 2018-05-08
HK1212273A1 (zh) 2016-06-10
JP7005551B2 (ja) 2022-02-04
HUE046292T2 (hu) 2020-02-28
JP7472080B2 (ja) 2024-04-22
CN104780976A (zh) 2015-07-15
WO2014028461A3 (en) 2014-04-17
CN104780976B (zh) 2019-01-01
AU2020200715B2 (en) 2022-05-12
JP2022001571A (ja) 2022-01-06
CN116271053A (zh) 2023-06-23
AU2022215282A1 (en) 2022-11-03
JP2018140982A (ja) 2018-09-13
CA3211094A1 (en) 2014-02-20
US10543183B2 (en) 2020-01-28
US20210220306A1 (en) 2021-07-22
JP6523502B2 (ja) 2019-06-05
US10945978B2 (en) 2021-03-16
US9399028B2 (en) 2016-07-26
JP2015532642A (ja) 2015-11-12
JP2019151646A (ja) 2019-09-12
AU2020200715A1 (en) 2020-02-20
AU2018226488A1 (en) 2018-09-27
JP2024041827A (ja) 2024-03-27
EP3626309A1 (en) 2020-03-25
US20180153833A1 (en) 2018-06-07
CN110037999B (zh) 2023-01-13
EP2882496A2 (en) 2015-06-17
EP2882496A4 (en) 2016-07-06
US20150073053A1 (en) 2015-03-12
US20200230090A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK2882441T3 (da) Behandling af immunrelaterede og inflammatoriske sygdomme
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
LT2885010T (lt) Tautopatijos gydymo būdai
PL2922850T3 (pl) Związki i sposoby ich stosowania
DK2850202T3 (da) Fremgangsmåder og grupper
IL240388A0 (en) Methods of treating melanoma
DK2958588T3 (da) Kombination af vaccination og hæmning af PD-1-reaktionsvejen
PT2817338T (pt) Moduladores de dll3 e métodos de utilização
DK2919923T3 (da) Holder-sortiment og rengøringsapparater til rengøring af åndedrætsapparater
DK2968208T3 (da) Behandling af kataplexi
EP2800590C0 (en) SLOTTED AND SIDE-OPENING CATHETER DEVICES
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
DK3076972T3 (da) Cancerbehandling med kombination af plinabulin og taxan
DK2723347T3 (da) Forebyggelse og behandling af inflammationstilstande
DK3646876T3 (da) Telomeraseinhibitoren imetelstat til behandling af myeloproliferative lidelser og myeloproliferative neoplasmer
DK3232663T3 (da) Fremgangsmåder og anordninger til afkodning
DK2914261T3 (da) Syntetisk letalitet og behandling af cancer
DK3292873T3 (da) Kombination af vaccination og hæmning af PD-1-vejen
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK3326642T3 (da) Langtidsvirkende koagulationsfaktorer og brugen deraf
DK3205683T3 (da) Sammensætninger og indretninger af poly-4-hydroxybutyrat